Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 4, 2026
- United Therapeutics reported $832.5 million in revenue for the quarter ended September 30, 2026, versus $799.5 million, while net income declined to $258.6 million from $338.7 million.
- 10-Q report · filed Nov 4, 2026
- United Therapeutics said Liquidia must remove PH-ILD from Yutrepia’s label after an adverse patent ruling and agreed to pay $330.4 million for past and future damages; Nebulized Tyvaso’s IPF application has an FDA goal date of April 26, 2027.
The audio replay and transcript follow the call.